Jan Lang

Cooley advised Autolus – a clinical-stage biopharmaceutical company developing next-generation programmed T-cell therapies – on its strategic collaboration with BioNTech, an immunotherapy company pioneering novel therapies for cancer and other serious diseases, to advance both companies’ autologous CAR-T programs toward commercialization, as well as a $350 million underwritten offering.

Cooley advised General Catalyst Partners, a venture capital firm providing early-stage and growth equity investments, as the lead investor in Helsing’s 209 million euro Series B financing.

Cooley advised Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, on its strategic collaboration with Moderna.

Cooley advised Condor, a German leisure airline, in its victory against the approval of Lufthansa’s 2020 state bailout.

A Cooley team advised Horizon Therapeutics, a specialty biopharmaceutical company, on its agreement to be acquired by Amgen. The approximately $28 billion merger would represent the third-largest all-cash transaction in the pharmaceutical sector in history and the biggest healthcare deal of 2022.